Lecture Details - Overview

1. LECTURE OVERVIEW
2. TABLE OF CONTENTS
3. FACULTY
4. TECHNICAL HELP

Continuing Education Information

• Discuss breast carcinogenesis and the impact of germline mutations on patient management
• Discuss advances in breast cancer imaging and early detection, including mammography, ultrasound, MRI, and PET scanning
• Review the clinical utility and limitations of sentinel lymph node biopsy
• Integrate diagnostic, prognostic, and predictive factors that provide biologic information about breast cancer subtypes into patient management decisions
• Integrate current staging guidelines into clinical decision making regarding local and systemic therapies
• Assess optimal radiation therapy strategies for treatment of patients with DCIS and early-stage and locally advanced breast cancer
• Critically analyze the data guiding the choice of adjuvant therapies for patients with low- and high-risk breast cancer
• Explore current and emerging strategies for ameliorating or eliminating therapy-associated adverse events
• Assess the evidence supporting an emphasis on quality of life and rehabilitation during and after breast cancer treatment
• Evaluate the evidence-based treatment recommendations for the management of patients with hormone-dependent and hormone-independent metastatic breast cancer
• Evaluate organ-specific therapeutic interventions for patients with metastatic disease to the CNS or skeleton
• Integrate palliative care strategies into treatment algorithms for metastatic disease

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from School of Breast Oncology have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Lauren E. Abrey
Research Funding – Genentech, Inc.; Novartis Pharmaceuticals Corporation; Schering-Plough Corporation

D. Craig Allred
Research Funding – Pfizer Inc.
Paid Consultant/Advisory Board – Dako; Genomic Health, Inc.; Pfizer Inc.
Major Stock/Investment Holder Clarient, Inc.

Douglas Arthur
Paid Consultant/Advisory Board – SenoRx

Harold Burstein
No relevant financial relationships to disclose

Lisa Carey
Research Funding – Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Pfizer Inc.
Paid Consultant/Advisory Board – Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Pfizer Inc.; sanofi-aventis U.S.
Speaker’s Bureau – Pfizer Inc.

Rowan Chlebowski
Research Funding – Eli Lilly and Company, Organon USA
Paid Consultant/Advisory Board – AstraZeneca, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Organon USA, sanofi-aventis U.S.
Speaker’s Bureau – AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation

David M. Euhus
No relevant financial relationships to disclose

Carol Fabian
Research Funding – Eisai Inc.; Genentech, Inc.; GlaxoSmithKline; ImClone Systems Incorporated; InterGenetics Incorporated; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Paid Consultant/Advisory Board – Pfizer Inc.
Other Remuneration – AstraZeneca

William J. Gradishar
Paid Consultant/Advisory Board – Abraxis Bioscience, LLC; AstraZeneca; Novartis Pharmaceuticals Corporation; Pfizer Inc.

Syed Hoda
No relevant financial relationships to disclose

Frankie Ann Holmes
Speaker’s Bureau – Novartis Pharmaceuticals Corporation
Other Remuneration – Pfizer Inc., Roche Pharmaceuticals

Claudine Isaacs
Speaker’s Bureau – Abraxis Bioscience, LLC; Genentech, Inc.; Genomic Health, Inc.; GlaxoSmithKline; Pfizer Inc.

Steven J. Kronowitz
No relevant financial relationships to disclose

Henry Kuerer
No relevant financial relationships to disclose

Eleftherios Mamounas
Paid Consultant/Advisory Board – Abraxis Bioscience, LLC; Bristol-Myers Squibb Company; Genentech, Inc.; Genomic Health, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche Pharmaceuticals; sanofi-aventis U.S.
Speaker’s Bureau – Genentech, Inc.; Genomic Health, Inc.; sanofi-aventis U.S.

Matthew Mayo
Employment (spouse) Celgene Corporation
Paid Consultant/Advisory Board – Genzyme Corporation

Anne McTiernan
Paid Consultant/Advisory Board – (spouse) Rosetta Genomics
Major Stock/Investment Holder (spouse) Merck & Co., Inc.

Anne Moore
No relevant financial relationships to disclose

Joanne Mortimer
No relevant financial relationships to disclose

Ruth M. O’Regan
Research Funding – Abraxis Bioscience, LLC; sanofi-aventis U.S.
Speaker’s Bureau – Genentech, Inc.; GlaxoSmithKline; Pfizer Inc.

Joyce O’Shaughnessy
Speaker’s Bureau – Abraxis Bioscience, LLC; AstraZeneca; Eli Lilly and Company; sanofi-aventis U.S.

Beth Overmoyer
Paid Consultant/Advisory Board – GlaxoSmithKline, sanofi-aventis U.S.

Soonmyung Paik
Paid Consultant/Advisory Board – Genentech, Inc.; GlaxoSmithKline

Edith A. Perez
Research Funding – AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; sanofi-aventis U.S.
Paid Consultant/Advisory Board – Bristol-Myers Squibb Company; Genentech, Inc.; Onyx Pharmaceuticals, Inc.; Pfizer Inc.; Roche Pharmaceuticals; sanofi-aventis U.S.

Lori J. Pierce
No relevant financial relationships to disclose

Elizabeth A. Rafferty
Research Funding – Hologic, Inc.

Peter Ravdin
Board of Directors/Other – Leadership Position adjuvant inc.
Other Remuneration – adjuvant inc.

Hope S. Rugo
Research Funding – Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche Pharmaceuticals
Speaker’s Bureau – AstraZeneca; Genomic Health, Inc.

David Schuster
Research Funding – Nihon Medi-Physics Co., Ltd.

Charles L. Shapiro
Research Funding – Genentech, Inc.
Paid Consultant/Advisory Board – Pfizer Inc.

Thomas Smith
No relevant financial relationships to disclose

Lawrence J. Solin
No relevant financial relationships to disclose

Richard Theriault
Research Funding – Amgen
Paid Consultant/Advisory Board – Amgen

Anthony Tolcher
Paid Consultant/Advisory Board – Abraxis Bioscience, LLC; Adnexus; Amgen; Anadys Pharmaceuticals, Inc.; ARIAD Pharmaceuticals, Inc.; Astellas Pharma Inc.; AstraZeneca; Biogen Idec; Centocor, Inc.; Chemokine Therapeutics Corp.; Curis Inc.; Cytokenetics, Inc.; Daiichi Sankyo Company, Ltd.; Dendreon Corporation; Eli Lilly and Company; Enzon Pharmaceuticals, Inc.; Exelixis, Inc.; FibroGen, Inc.; Five Prime Therapeutics, Inc.; Genentech, Inc.; Genetics Squared, Inc.; Genta Incorporated; Geron; HUYA Bioscience International; ImmunoGen, Inc.; Johnson & Johnson; Merck & Co., Inc.; MGI PHARMA; Micromet, Inc.; NCI Drug Development Group; Nektar; Nereus Pharmaceuticals; Nerviano Medical Sciences; Onyx Pharmaceuticals, Inc.; Paramount Biosciences; Pfizer Inc.; sanofi-aventis U.S.; Santaris Pharma A/S; Schering-Plough Corporation; Spectrum Chemicals and Laboratory Products; SuperGen; Symphogen A/S; Takeda Pharmaceuticals

Catherine Van Poznak
Paid Consultant/Advisory – Board Amgen

Jeffrey Weitzel
Speaker’s Bureau – Myriad Genetics, Inc.

Eric P. Winer
Research Funding – Genentech, Inc.; GlaxoSmithKline

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

• Microsoft Internet Explorer Downloads (Outside Source)
• Mozilla Firefox Product Page (Outside Source)
• Adobe Flash Player 9 (Outside Source)

Macintosh Users
Compatible Web browsers include

• Firefox (Outside Source)
• Apple Safari (Outside Source).
• Adobe Flash Player 9 (Outside Source)

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians' Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians' Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians' Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, School of Breast Oncology
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com

Educational Grants

An educational grant for this activity was provided by:

1. Genentech BioOncology
2. Bristol-Myers Squibb
3. Novartis Oncology
4. AstraZeneca/Abraxis BioScience
5. sanofi-aventis U.S.